J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):279-83.
CLEAR test provides a novel method of analysis by combining inference for differential expression and variability. Frozen tumor specimens from 14 (3 coded Stage I, 5 Stage II, 2 Stage III and 4 Stage IV) colon cancer patients were obtained. Archived primary tumor samples were collected at the time of surgery and normal colon mucosae (controls specimens) were also collected. The studied transcriptomes were clustered using hierarchical agglomeration with Ward's method and Tchebychev distance. The separable groups of transcriptomes were classified as high clinical stage of adenocarcinoma (HCS; stages II-IV), low clinical stage of adenocarcinoma (LCS; stages I and 3 controls), and two normal colon mucosae (controls N1 and N2). The results of the CLEAR-test algorithm in normal colon specimens and adenocarcinoma specimens with low and high clinical stage showed 50 most and 50 least significant genes. The list of differential genes (p<0.01) in normal colon specimens and adenocarcinoma specimens with low and high clinical stage presented 58 genes.
CLEAR 测试提供了一种新的分析方法，通过结合差异表达和变异性推断。从 14 位（3 位编码为 I 期、5 位 II 期、2 位 III 期和 4 位 IV 期）结肠癌患者中获得了冷冻肿瘤标本。收集了手术时的存档原发性肿瘤样本，并收集了正常结肠黏膜（对照样本）。使用层次聚类法和切比雪夫距离对研究的转录组进行聚类。可分离的转录组组被分类为高临床阶段腺癌（HCS；II-IV 期）、低临床阶段腺癌（LCS；I 期和 3 期对照）和两个正常结肠黏膜（对照 N1 和 N2）。在正常结肠标本和低临床和高临床阶段腺癌标本中的 CLEAR-test 算法结果显示了 50 个最显著和 50 个最不显著的基因。在正常结肠标本和低临床和高临床阶段腺癌标本中的差异基因列表（p<0.01）显示了 58 个基因。
